Drug Trial Radar · NCT06962865
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
Last checked: Nov 19, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
May 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the efficacy and safety of RC108 in combination with Furmonertinib against Furmonertinib for treatment of EGFR mutation combined with MET-positive unresectable locally advanced or recurrent metastatic NSCLC
Conditions
- Non-Small Cell Lung Cancer
Interventions
RC108Drug
RC108 in Combination With Furmonertinib
Furmonertinib Mesilate Tablets MonotherapyDrug
Furmonertinib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: 24 months
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chest Hospital,Capital Medical Unniversity
Beijing, China · Recruiting
The Fifth Medical Center of Chinese People's Liberation Army General Hospital
Beijing, China · Recruiting
Binzhou Medical University Hospital
Binzhou, China · Recruiting
Jilin Cancer Hospital
Changchun, China · Recruiting
The Second Xiangya Hospital Of Central South University
Changsha, China · Recruiting
Changzhou Cancer Hospital
Changzhou, China · Recruiting
Sichuan Cancer Hospital
Chengdu, China · Recruiting
West China hospitial of SiChuan University
Chengdu, China · Recruiting
Chongqing University Cancer Hospitai
Chongqing, China · Recruiting
Fujian Cancer Hospital
Fuzhou, China · Recruiting
Ganzhou cancer Hospitial
Ganzhou, China · Recruiting
Affiliated Cancer Hospital of Guangzhou Medical University
Guangzhou, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Guilin, China · Recruiting
The Second Affiliated Hospital of Guilin Medical University
Guilin, China · Recruiting
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Hangzhou, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, China · Recruiting
Anhui Provincial cancer hospital
Hefei, China · Recruiting
The First hospitial of Anhui Medicine University
Hefei, China · Recruiting
Jinan Central Hospital
Jinan, China · Recruiting
Shandong Cancer Hospital
Jinan, China · Recruiting
The First hospitial of Lanzhou University
Lanzhou, China · Recruiting
Linyi People's Hospital
Linyi, China · Recruiting
THE FIRST HOSPITAI OF CHINA MEDICAL UNIVERSITY,No. 155, Nanjing North Street, Heping District, Shenyang City, Liaoning Province
Shenyang, China · Recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China · Recruiting
Shanxi Cancer Hospital
Taiyuan, China · Recruiting
Taizhou hospitial of Zhejiang province
Taizhou, China · Recruiting
Tianjin Chest Hospital
Tianjin, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China · Recruiting
Xiangyang Central Hospital
Xiangyang, China · Recruiting
The Second People's Hospital of Yibin City
Yibin, China · Recruiting
Yiyang Central Hospital
Yiyang, China · Recruiting
Yueyang Central Hospital
Yueyang, China · Recruiting
Yunnan Cancer Hospital
Yunnan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.